IMVT-1402: • Dose 1 subcutaneous (SC) once weekly (QW) for 12 weeks (Period 1)
IMVT-1402: * Dose 2 SC QW for 12 weeks (Period 1) * Dose 2 SC QW for 14 weeks (Period 2) * Dose 2 SC QW for 52 weeks (Period 3)
Placebo: • Placebo SC QW for 12 weeks (Period 1)
IMVT-1402: * Dose 1 SC QW for 14 weeks (Period 2) * Dose 1 SC QW for 52 weeks (Period 3)
The purpose of the study is to assess the efficacy, safety and tolerability of IMVT-1402 in adult participants with mild to severe generalized myasthenia gravis.
| Facility | City | Region | Status |
|---|---|---|---|
| Site Number - 1056 | Huntsville | Alabama | Recruiting |
| Site Number - 1041 | Mobile | Alabama | Recruiting |
| Site Number - 1017 | Phoenix | Arizona | Recruiting |
| Site Number - 1025 | Scottsdale | Arizona | Recruiting |
| Site Number - 1042 | Tucson | Arizona | Recruiting |
| Site Number - 1010 | Carlsbad | California | Recruiting |
| Site Number - 1028 | Irvine | California | Recruiting |
| Site Number - 1023 | Los Angeles | California | Recruiting |
| Site Number - 1029 | Rancho Mirage | California | Recruiting |
| Site Number - 1004 | San Francisco | California | Recruiting |
| Site Number - 1027 | Fort Collins | Colorado | Recruiting |
| Site Number - 1001 | New Haven | Connecticut | Recruiting |
| Site Number - 1024 | Washington D.C. | District of Columbia | Recruiting |
| Site Number - 1006 | Clearwater | Florida | Recruiting |
| Site Number - 1037 | Ormond Beach | Florida | Recruiting |
| Site Number - 1002 | Port Charlotte | Florida | Recruiting |
| Site Number - 1050 | Rockledge | Florida | Recruiting |
| Site Number - 1007 | Tampa | Florida | Recruiting |
| Site Number - 1014 | Atlanta | Georgia | Recruiting |
| Site Number - 1043 | Augusta | Georgia | Recruiting |
| Site Number - 1054 | Schaumburg | Illinois | Recruiting |
| Site Number - 1022 | Lexington | Kentucky | Recruiting |
| Site Number - 1032 | Nicholasville | Kentucky | Recruiting |
| Site Number - 1046 | New Orleans | Louisiana | Recruiting |
| Site Number - 1049 | Foxborough | Massachusetts | Recruiting |
| Site Number - 1026 | Detroit | Michigan | Recruiting |
| Site Number - 1005 | East Lansing | Michigan | Recruiting |
| Site Number - 1018 | Omaha | Nebraska | Recruiting |
| Site Number - 1019 | Totowa | New Jersey | Recruiting |
| Site Number - 1036 | New York | New York | Recruiting |
| Site Number - 1034 | New York | New York | Recruiting |
| Site Number - 1020 | Chapel Hill | North Carolina | Recruiting |
| Site Number - 1013 | Durham | North Carolina | Recruiting |
| Site Number - 1044 | Raleigh | North Carolina | Recruiting |
| Site Number - 1038 | Cincinnati | Ohio | Recruiting |
| Site Number - 1045 | Oklahoma City | Oklahoma | Recruiting |
| Site Number - 1011 | Yukon | Oklahoma | Recruiting |
| Site Number - 1031 | Eugene | Oregon | Recruiting |
| Site Number - 1030 | Charleston | South Carolina | Recruiting |
| Site Number - 1015 | Charleston | South Carolina | Recruiting |
+ 48 more sites — see the full list on the official registry below.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07039916 on ClinicalTrials.gov ↗ ← All trials in the USA